The resurgence of swine-origin influenza A (H1N1)

Cleveland Clinic Journal of Medicine

Volumn 76, Issue 6, 2009, Pages 337-343

  Mossad, Sherif Beniameen ^a,b  

^a LERNER RESEARCH INSTITUTE   (United States)

^b CLEVELAND CLINIC LERNER COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; INFLUENZA VACCINE;

ANIMAL; ANIMAL DISEASE; ARTICLE; EPIDEMIC; HEALTH; HUMAN; HYGIENE; IMMUNOLOGY; INFLUENZA; INFLUENZA VIRUS A H1N1; ORTHOMYXOVIRUS INFECTION; RISK FACTOR; SWINE; ZOONOSIS;

ANIMALS; ANTIVIRAL AGENTS; DISEASE OUTBREAKS; HUMANS; HYGIENE; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA VACCINES; INFLUENZA, HUMAN; ORTHOMYXOVIRIDAE INFECTIONS; RISK FACTORS; SWINE; WORLD HEALTH; ZOONOSES;

EID: 67149123934     PISSN: 08911150     EISSN: None     Source Type: Journal    
DOI: 10.3949/ccjm.76a.09047     Document Type: Article

References (24)

1. Belshe RB. Implications of the emergence of a novel H1 influenza virus. N Engl J Med 2009 May 7; doi:10.1056/NEJMe0903995.
2. Ducatez MF, Webster RG, Webby RJ. Animal influenza epidemiology. Vaccine 2008; 26(suppl 4):D67-D69.
3. Myers KP, Olsen CW, Gray GC. Cases of swine influenza in humans: a review of the literature. Clin Infect Dis 2007; 44:1084-1088.
4. Shinde V, Bridges CB, Uyeki TM, et al. Triple-reassortant swine influenza A (H1) in humans in the United States, 2005-2009. N Engl J Med 2009 May 7; doi:10.1056/NEJMoa0903812.
5. Sandbulte MR, Jimenez GS, Boon AC, Smith LR, Treanor JJ, Webby RJ. Cross-reactive neuraminidase antibodies afford partial protection against H5N1 in mice and are present in unexposed humans. PLoS Med 2007; 4(2):e59. doi:10.1371/journal. pmed.0040059.
6. Belshe RB. The origins of pandemic influenza-lessons from the 1918 virus. N Engl J Med 2005; 353:2209-2211.
7. Miller MA, Viboud C, Balinska M, Simonsen L. The signature features of influenza pandemics-implications for policy. N Engl J Med 2009 May 7; doi:10.1056/NEJMp0903906.
8. Morens DM, Taubenberger JK, Fauci AS. Predominant role of bacterial pneumonia as a cause of death in pandemic influenza: implications for pandemic influenza preparedness. J Infect Dis 2008; 198:962-970.
9. Viboud C, Grais RF, Lafont BAP, Miller MA, Simonsen L. Multinational impact of the 1968 Hong Kong influenza pandemic: evidence for a smoldering pandemic. J Infect Dis 2005; 192:233-248.
10. Novel Swine-Origin Influenza A (H1N1) Virus Investigation Team. Emergence of a novel swine-origin influenza A (H1N1) virus in humans. N Engl J Med 2009 May 7; doi:10.1056/NEJMoa0903810.
11. US Centers for Disease Control and PreventionC. Swine-origin influenza A (H1N1) virus infections in a school-New York City, April 2009. MMWR 2009; 58 (Dispatch):1-3.
12. Call SA, Vollenweider MA, Hornung CA, Simel DL, McKinney WP. Does this patient have influenza? JAMA 2005: 293:987-997.
13. Baden LR, Drazen JM, Kritek PA, Curfman GD, Morrissey S, Campion EW. H1N1 influenza A disease-information for health professionals. N Engl J Med 2009 May 7; doi:10.1056/NEJMe0903992.
14. Brownstein JS, Freifeld CC, Madoff LC. Influenza A (H1N1) virus, 2009-online monitoring. N Engl J Med 2009 May 7; doi:10.1056/NEJMp0904012.
15. Markel H, Lipman HB, Navarro JA, et al. Nonpharmaceutical interventions implemented by US cities during the 1918-1919 influenza pandemic. JAMA 2007; 298:644-654.
16. Jefferson T, Foxlee R, Del Mar C, et al. Physical interventions to interrupt or reduce the spread of respiratory viruses: systematic review. BMJ 2008; 336(7635):77-80.
17. Omer SB, Salmon DA, Orenstein WA, deHart MP, Halsey N. Vaccine refusal, mandatory immunization, and the risks of vaccinepreventable diseases. N Engl J Med 2009; 360:1981-1988.
18. Sahni R, Mossad SB. Controlling pandemic influenza through vaccination programs. Future Virol 2009; 4:271-276.
19. Hughes RA, Charlton J, Latinovic R, Gulliford MC. No association between immunization and Guillain-Barré syndrome in the United Kingdom, 1992 to 2000. Arch Intern Med 2006; 166:1301-1304.
20. Sivadon-Tardy V, Orlikowski D, Porcher R, et al. Guillain-Barré syndrome and influenza virus infection. Clin Infect Dis 2009; 48:48-56.
21. US Centers for Disease Control and Prevention. Update: drug susceptibility of swine-origin influenza A (H1N1) viruses, April 2009. MMWR May 1, 2009; 58(16):433-435.
22. Wu JT, Leung GM, Lipsitch M, Cooper BS, Riley S. Hedging against antiviral resistance during the next influenza pandemic using small stockpiles of an alternative chemotherapy. PLoS Med 2009; e1000085. doi:10.1371/journal.pmed.1000085.
23. Luke TC, Kilbane EM, Jackson JL, Hoffman SL. Meta-analysis: convalescent blood products for Spanish influenza pneumonia: a future H5N1 treatment? Ann Intern Med 2006; 145:599-609.
24. Fedson DS. Confronting an influenza pandemic with inexpensive generic agents: can it be done? Lancet Infect Dis 2008; 8:571-576.